Net sales came in higher than expected. The sales, amounting to SEK69m, were more in line with our p...
Redeye is encouraged to see that Railcare has raised its financial targets in conjunction with annou...
Redeye comments on Tessin’s Q4 results, which showed lower sales than expected due to limited capita...
Nettoomsättningen kom in högre än väntat. Försäljningen som landade på SEK69m var mer i linje med vå...
Redeye has updated its estimates for Safeture following the Q4 2023 report.
Q4 sales lower than expected, mainly on delayed product sales Strong CF driven by WC improvements Sh...
Redeye comments on Gasporox's Q4 report, which was in line with estimates.
Redeye thinks Arise’s Q4 2023 report came in weaker than expected.
Redeye comments on Carasent's Q4 2023 report, which came in in line on sales, but slightly lower on ...
Redeye provides an initial take on Optomed’s Q4 2023 report.
Raute’s Q4 figures were slightly mixed relative to our estimates as Services and Analyzers performed...
Solteq’s Q4 results were as expected weak and slightly below our estimates.
Redeye comments on Maximum Entertainments Q4-results which came in ahead of expectations driven by s...
Redeye comments on SDS’s Q4 results, which came in weaker than expected in terms of sales and profit...
ARR +6% y-o-y, 3% below ABGSCe Surprisingly large beat on EBITDA (+99% vs.
Redeye see a softer than anticipated Q4 report from Genovis which came in below expectations on both...
Vaisala’s Q4 EBIT missed our estimates mainly due to weaker than expected gross margin development.
Redeye's first comments on the Q4 report this morning.
Doro deliveres good topline growth of 9% with a Ebit margin of 9% as Nordics and the UK particular s...
NoHo Partners reported Q4 EBIT of EUR 10.6m, -5% versus Vara consensus and -6% versus our estimate.
